Ozempic History and Development: From GLP-1 Discovery to a Global Prescription

The Isolation of GLP-1: Where the Story Begins

The history of Ozempic starts not in a pharmaceutical lab but in basic endocrinology research during the early 1980s. GLP-1 was identified as a product of the proglucagon gene, secreted by intestinal L-cells in response to nutrient ingestion, and recognized as a potent stimulator of insulin secretion.

In 1987, researchers including Svetlana Mojsov, Gordon Weir, and Joel Habener published work establishing that the truncated form GLP-1(7-36) amide was the biologically active peptide responsible for the incretin effect 1. This was the form that bound to pancreatic beta-cell receptors and triggered glucose-dependent insulin release. The finding was significant because it meant the hormone would not drive blood sugar dangerously low on its own. Insulin secretion only ramped up when glucose was already elevated.

The problem was practical. Native GLP-1 is degraded by the enzyme dipeptidyl peptidase-4 (DPP-4) within approximately two minutes of entering the bloodstream 2. A therapeutic built on unmodified GLP-1 would require continuous intravenous infusion. That limitation defined the next 25 years of drug development: every GLP-1-based therapy that followed was, at its core, an engineering project to make the molecule last longer.

Early GLP-1 Receptor Agonists: Exenatide and Liraglutide

The first commercial GLP-1 receptor agonist took an unconventional path to the clinic. Exendin-4, a peptide found in the saliva of the Gila monster lizard (Heloderma suspectum), shares about 53% amino acid homology with human GLP-1 but resists DPP-4 cleavage naturally 3. Amylin Pharmaceuticals developed it as exenatide (Byetta), which the FDA approved in April 2005. It required twice-daily injections.

Novo Nordisk pursued a different strategy. Rather than borrowing a reptilian peptide, the company modified human GLP-1 itself. Their first product, liraglutide (Victoza), incorporated a C-16 fatty acid chain attached to a lysine residue, enabling the molecule to bind reversibly to serum albumin 4. This albumin-binding trick slowed renal clearance and extended the half-life to approximately 13 hours. The FDA approved liraglutide for type 2 diabetes in January 2010. Dosing was once daily.

But once daily was not the end goal. The question Novo Nordisk's chemistry team asked next: could further modifications push that half-life from 13 hours to a full week?

Molecular Engineering of Semaglutide: Three Changes That Made the Difference

Semaglutide is 94% homologous to native human GLP-1(7-37). Three discrete structural modifications account for its week-long duration of action, and a 2015 paper in the Journal of Medicinal Chemistry by Lau and colleagues at Novo Nordisk detailed each one 5.

Modification 1: Aib8 substitution. The alanine at position 8 was replaced with alpha-aminoisobutyric acid (Aib). Position 8 is the primary cleavage site for DPP-4. The Aib substitution creates steric hindrance that blocks enzymatic access, making the molecule resistant to DPP-4 degradation.

Modification 2: Arg34 substitution. Lysine at position 34 was replaced with arginine. This change eliminated a secondary fatty acid attachment point, ensuring the C-18 acyl chain (see below) attached only at position 26, which improved binding consistency and pharmacokinetic predictability.

Modification 3: C-18 fatty diacid spacer at Lys26. A spacer consisting of a mini-PEG linker and a C-18 octadecanedioic fatty diacid was conjugated to the lysine at position 26. This side chain binds to albumin with higher affinity than the C-16 chain used in liraglutide 5. The result: a plasma half-life of approximately 165 hours (roughly 7 days), enabling true once-weekly dosing.

As Lau et al. noted, "The improved albumin affinity achieved through the extended linker and C-18 fatty diacid was the primary driver of the prolonged pharmacokinetic profile" 5. The molecule entered clinical development in 2008 under the internal designation NN9535.

How Ozempic Works: Mechanism of Action

Semaglutide activates the GLP-1 receptor, a G-protein-coupled receptor expressed on pancreatic beta cells, the hypothalamus, the brainstem, the heart, and the gastrointestinal tract 2. The downstream effects span multiple organ systems.

Pancreas. GLP-1 receptor activation stimulates cyclic AMP (cAMP) signaling in beta cells, amplifying glucose-dependent insulin secretion. It simultaneously suppresses glucagon release from alpha cells when blood glucose is elevated 6. The glucose-dependent nature of this mechanism is clinically relevant: the drug carries a low intrinsic risk of hypoglycemia when used without sulfonylureas or insulin.

Stomach. Semaglutide slows gastric emptying, which blunts postprandial glucose spikes. Gastric motility studies have shown a 10% to 30% delay in emptying rate during the first weeks of treatment, though this effect partially attenuates over time 6.

Brain. GLP-1 receptors in the arcuate nucleus, paraventricular nucleus, and area postrema mediate appetite suppression. Functional MRI studies in patients receiving semaglutide have demonstrated reduced activation in brain regions associated with food craving and reward processing 7. This central nervous system effect accounts for much of the weight loss observed in trials.

Cardiovascular system. GLP-1 receptors on cardiomyocytes and vascular endothelium appear to reduce inflammation and improve endothelial function. The 2023 SELECT trial (N=17,604) demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg in patients with established cardiovascular disease but without diabetes 8.

The SUSTAIN Trial Program: Building the Evidence Base

Novo Nordisk launched the SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) clinical program to establish semaglutide's efficacy and safety across a range of comparators and patient populations. Seven core trials enrolled over 8,000 patients between 2013 and 2016 9.

SUSTAIN-1 (N=388) tested semaglutide 0.5 mg and 1.0 mg against placebo over 30 weeks. HbA1c dropped by 1.45% at the 0.5 mg dose and 1.55% at 1.0 mg, compared with 0.02% for placebo 9.

SUSTAIN-2 (N=1,231) compared semaglutide against sitagliptin 100 mg over 56 weeks. Semaglutide 1.0 mg reduced HbA1c by 1.6% versus 0.5% for sitagliptin, and produced 6.1 kg weight loss versus 1.9 kg 10.

SUSTAIN-6 (N=3,297) was a two-year cardiovascular outcomes trial. Semaglutide reduced the composite endpoint of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 26% (hazard ratio 0.74 to 95% CI 0.58-0.95, P=0.02) 11. This trial was pre-approval, designed to satisfy the FDA's 2008 cardiovascular safety guidance for diabetes drugs. It did more than demonstrate safety. It showed benefit.

SUSTAIN-7 (N=1,201) compared semaglutide head-to-head with dulaglutide (Trulicity) over 40 weeks. At the 1.0 mg dose, semaglutide achieved an HbA1c reduction of 1.8% versus 1.4% for dulaglutide 1.5 mg. Weight loss was 6.5 kg with semaglutide versus 3.0 kg with dulaglutide 12. The Endocrine Society's 2022 clinical practice guideline cited SUSTAIN-7 data when recommending GLP-1 receptor agonists with demonstrated cardiovascular or weight-loss superiority as preferred second-line agents after metformin 13.

Dr. John Buse, then-president of the American Diabetes Association, stated after the SUSTAIN data readout: "The glycemic efficacy and weight reduction seen with semaglutide set a new benchmark for injectable GLP-1 receptor agonist therapy" 12.

FDA Approval and Subsequent Expansions

The FDA approved Ozempic (semaglutide injection, 0.5 mg and 1.0 mg) on December 5, 2017, for the treatment of type 2 diabetes in adults as an adjunct to diet and exercise 14. The approval was based on the SUSTAIN program data, with particular weight given to the cardiovascular signal from SUSTAIN-6.

Two label milestones followed. In January 2020, the FDA added a cardiovascular indication: Ozempic was approved to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease 14. In March 2022, the FDA approved the 2.0 mg dose, providing a higher-dose option for patients not reaching glycemic targets on 1.0 mg.

The semaglutide molecule also branched into other formulations. Rybelsus (oral semaglutide, 3/7/14 mg) received approval in September 2019 for type 2 diabetes. Wegovy (semaglutide 2.4 mg injection) was approved in June 2021 specifically for chronic weight management.

Why Semaglutide Outperformed Earlier GLP-1 Agonists

The clinical superiority of semaglutide over older GLP-1 receptor agonists is not subtle. Head-to-head data from SUSTAIN-7 showed semaglutide 1.0 mg produced more than double the weight loss of dulaglutide 1.5 mg (6.5 kg vs. 3.0 kg) 12. Against exenatide extended-release in SUSTAIN-3 (N=813), semaglutide 1.0 mg achieved an HbA1c reduction of 1.5% versus 0.9%, with 5.6 kg weight loss versus 1.9 kg over 56 weeks 15.

Three pharmacological factors explain the gap. First, semaglutide's higher albumin-binding affinity yields more stable plasma concentrations, reducing peak-to-trough fluctuation and producing more consistent receptor occupancy across the dosing interval 5. Second, semaglutide crosses the blood-brain barrier more effectively than liraglutide or dulaglutide, based on preclinical data showing higher central nervous system penetration relative to plasma exposure 7. Third, the molecule's receptor binding kinetics favor sustained cAMP signaling with reduced receptor internalization, a property that may amplify downstream insulin secretion per unit of receptor engagement 2.

The Weight Loss Effect and Off-Label Prescribing Surge

While Ozempic was developed and approved for glucose control, weight loss data from the SUSTAIN trials triggered widespread off-label prescribing for obesity. SUSTAIN-1 through 7 consistently showed weight reductions of 3.5 to 7.3 kg at the 0.5 to 1.0 mg doses in patients with type 2 diabetes 9.

The higher-dose formulation studied specifically for obesity, semaglutide 2.4 mg (later branded as Wegovy), produced even larger effects. STEP-1 (N=1,961) enrolled adults with BMI ≥30 (or ≥27 with at least one comorbidity) without diabetes. Mean weight loss at 68 weeks was 14.9% of body weight with semaglutide versus 2.4% with placebo 16. This result exceeded any prior pharmacotherapy trial for obesity.

Off-label demand for Ozempic itself created supply shortages beginning in 2022 that persisted into 2024. The FDA listed Ozempic on its drug shortage database, and Novo Nordisk invested over $6 billion in manufacturing expansion to address capacity constraints 14.

From SELECT to the Present: Cardiovascular and Beyond

The SELECT trial, published in the New England Journal of Medicine in November 2023, marked a turning point for semaglutide's clinical profile. This randomized, double-blind trial enrolled 17,604 adults aged 45 or older with established cardiovascular disease, a BMI of 27 or greater, and no diabetes 8. Semaglutide 2.4 mg reduced the primary composite endpoint of cardiovascular death, nonfatal MI, or nonfatal stroke by 20% (hazard ratio 0.80 to 95% CI 0.72-0.90, P<0.001).

Dr. A. Michael Lincoff, the trial's lead investigator at the Cleveland Clinic, commented: "These results establish that semaglutide reduces cardiovascular risk in overweight and obese individuals independent of diabetes status" 8.

Active research continues into semaglutide's effects on metabolic-associated steatotic liver disease (MASLD), chronic kidney disease, heart failure with preserved ejection fraction, and obstructive sleep apnea. The FLOW trial (N=3,533) demonstrated a 24% reduction in kidney disease progression in patients with type 2 diabetes and chronic kidney disease 17. Each new dataset extends the clinical relevance of a molecule whose development began with a two-minute peptide that researchers refused to give up on.